Linden Capital Partners has announced it will make a majority investment in Aspirion.

Aspirion, based in Columbus, Ga., is a full-service revenue cycle management company. Founded in 2006, the company specializes in motor vehicle accident, third-party liability, workers’ compensation, Veterans Administration, out-of-state Medicaid, and Medicaid eligibility and enrollment claims.

Linden, based in Chicago,…

Sverica Capital Management has announced it has completed a strategic investment in SG Homecare.

SG Homecare, based in Tustin, Calif., and founded in 2001, is a provider of durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) to home-based patients throughout California.

Sverica, with offices in Boston and San Francisco, pursues entrepreneur-operated businesses in the…

Ampersand Capital Partners has completed an investment in AnaBios Corp., according to a news release.

AnaBios, based in San Diego, is preclinical contract research organization. Founded in 2009, the company’s research focuses primarily on areas including cardiac disease and safety, pain, polycystic kidney disease and neurodegeneration.

Ampersand, based in Wellesley, Mass., is…

Northlane Capital Partners has announced it has invested in SAI MedPartners.

SAI, based in Reading, Pa., is a consultancy providing guidance and analytics to the pharmaceutical, biotechnology and medical device industries. Founded in 1978, the company has offices across the Americas, Europe, India and Asia.

NCP, based in Bethesda, Md., is a middle…

RoundTable Healthcare Partners has announced it has completed a majority investment into Polymedco.

Polymedco, based in Cortlandt Manor, N.Y., is a marketer and distributor of diagnostic tests primarily used for colorectal cancer screening and the diagnosis of cardiac conditions. Founded in 1980, the company’s products are sold to distributors, hospital systems, payors and laboratories…

The Supreme Court (Court) will soon decide whether to take up a critical (and long-running) issue concerning applicability of Federal Rule of Civil Procedure 9(b) pleading standards in False Claim Act (FCA) suits. To satisfy Rule 9(b)’s particularity requirement for fraud allegations, FCA plaintiffs generally have needed to detail specific false claims submitted by defendants. The question that has divided federal courts for more than a decade is whether a plaintiff instead may plead the submission of false claims more generally without identifying specific claims if they provide sufficient reliable indicia that false claims were submitted—such as the qui tam plaintiff’s personal knowledge of or participation in the alleged fraudulent practices that are the basis of the FCA action. The issue is particularly salient in cases where the government declines intervention and the whistleblower (or relator), who is often a former employee of the defendant, may not have access to the relevant invoices at issue.[1]

Frazier Healthcare Partners has announced the acquisition of Apollo Intelligence.

Apollo, based in Watertown, Mass., is a provider of data and insights to the healthcare and life science industries. Apollo launched in 2019 with the acquisition of InCrowd, a provider of automated insights for the life sciences. In 2020, the company acquired Survey Healthcare Global,…

On June 3, 2022, the Financial Crimes Enforcement Network (FinCen) issued an Advance Notice of Proposed Rulemaking  proposing public comment on the enactment of a no-action letter process.  This Advanced Notice follows FinCen’s Report to Congress submitted in June 2021 that was based on FinCen’s consultation with the Attorney General, State bank supervisors, State credit union supervisors, and other Federal agencies and regulators.  In its report, FinCen evaluated the difficulties it faces because of the overlap between its enforcement authority and other regulators.  FinCen also examined the benefits and concerns on how a no-action letter process could affect illicit finance risks.  FinCen stated that the primary benefits of a no-action letter process “are that it could promote a robust and productive dialogue with the public, spur innovation among financial institutions, and enhance the culture of compliance and transparency in the application and enforcement of BSA.”  Ultimately, FinCen concluded that it should establish a rulemaking to create a no-action letter process.

Sheridan Capital Partners has announced the sale of Dermatologists of Central States (DOCS) to SkyKnight Capital.

DOCS, headquartered in Cincinnati, is a provider of management services to dermatology practices in the Midwest and Southeast United States. The organization has a presence in seven states: Illinois, Indiana, Michigan, North Carolina, Ohio, Pennsylvania and West Virginia.…